Cognition Therapeutics financials
$0.9544+1.71%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$7.7M | -$8.8M | -$13.7M | -$6.4M | -$14.0M | -$13.8M | -$10.7M | -$14.5M | -$14.7M | -$14.1M | -$15.2M | -$14.7M |
| Net income | -$3.9M | -$4.6M | -$3.3M | -$4.9M | -$6.7M | -$8.5M | -$7.8M | -$9.9M | -$7.0M | -$9.2M | -$8.1M | -$6.7M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.04 | $-0.05 | $-0.04 | $-0.06 | $-0.11 | $-0.14 | $-0.18 | $-0.25 | $-0.18 | $-0.27 | $-0.26 | $-0.22 |
| EBITDA | -$7.7M | -$8.8M | -$13.7M | -$6.4M | -$14.0M | -$13.8M | -$10.7M | -$14.4M | -$14.7M | -$14.1M | -$15.2M | -$14.7M |
| Operating cash flow | -$3.1M | -$5.5M | -$3.4M | -$5.7M | -$5.6M | -$9.9M | -$8.4M | -$6.9M | -$6.0M | -$7.2M | -$5.5M | -$4.2M |
| Free cash flow | -$3.1M | -$5.5M | -$3.4M | -$5.7M | -$5.6M | -$9.9M | -$8.4M | -$6.9M | -$6.0M | -$7.2M | -$5.5M | -$4.2M |
| Diluted shares | 90.6M | 89.2M | 87.6M | 78.0M | 63.7M | 61.8M | 44.7M | 40.4M | 40.1M | 33.7M | 31.0M | 30.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $34.0M | $31.1M | $36.8M | $39.3M | $10.7M | $16.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $38.9M | $36.1M | $48.4M | $43.4M | $19.6M | $23.5M |
| Total liabilities | $5.9M | $6.2M | $14.1M | $6.9M | $12.6M | $11.2M |
| Shareholders' equity | $33.0M | $29.9M | $34.3M | $36.5M | $7.0M | $12.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology